Transfusion reactions associated with COVID‐19 convalescent plasma therapy for SARS‐CoV‐2

• Published in: Transfusion (Philadelphia, Pa.) Vol. 61; no. 1; pp. 78 - 93
• Main Authors: Nguyen, Freddy T., Akker, Tayler, Lally, Kimberly, Lam, Hansen, Lenskaya, Volha, Liu, Sean T. H., Bouvier, Nicole M., Aberg, Judith A., Rodriguez, Denise, Krammer, Florian, Strauss, Donna, Shaz, Beth H., Rudon, Louella, Galdon, Patricia, Jhang, Jeffrey S., Arinsburg, Suzanne A., Baine, Ian
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.01.2021; Wiley Subscription Services, Inc
• Subjects: ABO system; Adverse events; Aged; Blood group B; Blood groups; Blood Transfusion; Coronaviridae; Coronaviruses; COVID-19; COVID-19 - therapy; Demographics; Demography; Female; FFP transfusion; Humans; Immunization, Passive - methods; immunology (other than RBC serology); Male; Middle Aged; Parameters; Patients; Retrospective Studies; Risk analysis; Risk factors; SARS-CoV-2 - pathogenicity; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; Transfusion; transfusion practices (adult); Transfusion Reaction; Viral diseases; transfusion practices (adult); immunology (other than RBC serology); FFP transfusion

Background Convalescent plasma (CP) for treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has shown preliminary signs of effectiveness in moderate to severely ill patients in reducing mortality. While studies have demonstrated a low risk of serious adverse events, the compreh...